Circle CVI Advances Cardiovascular Imaging Innovation with cvi42 v6.5New cvi42 v6.5 capabilities automate 4D Flow preprocessing, streamline CT workflow, and enhance reporting to help clinicians move from acquisition to insight faster
Circle Cardiovascular Imaging Expands cvi42 Platform with Advanced Vascular CT CapabilitiesNew solution brings advanced vascular analysis into the cvi42 cardiovascular imaging ecosystem
Circle Cardiovascular Delivers a Unified Cardiac Imaging PlatformCircle CVI Launches cvi42 v6.4: One Platform for Every Advanced Cardiac Imaging Need.
Expanded Insurance Coverage Validates Circle’s AI Approach to Coronary Plaque EvaluationCoverage unlocks reimbursable AI plaque quantification, advancing coronary risk assessment in everyday cardiology practice
Unlock Practice Growth: Experience cvi42 at RSNA 2025See Why Leading Radiologists Are Upgrading to cvi42 This November - Visit Circle at RSNA Booth #7961
Circle CVI Announces FDA Clearance for cvi42 | Plaque for Coronary Artery Disease EvaluationCALGARY, Alberta, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Circle Cardiovascular Imaging Inc. (Circle CVI), a global leader in cardiovascular imaging solutions, today announced that its cvi42 | Plaque solution has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and is now available for clinical use in the United States. This innovative, AI-enabled solution allows clinicians to perform comprehensive coronary plaque analysis directly on-premise, enhancing diagnostic workflows and patient care.
